NEU 0.94% $13.92 neuren pharmaceuticals limited

Neuren Media and Analyst Coverage, page-1342

  1. 937 Posts.
    lightbulb Created with Sketch. 324
    Yeah agree totally different. Maybe I was not clear enough in my explanation but I meant that we could use some of the hype that Ozempic has.

    I agree with Tangent that the applicability is broad and I would argue that a drug with the potential of 2591 would be even bigger if its applicability was understood better and marketed more widely.

    A drug that can improve memory, learning, socialisation and cognition is something every right minded person on the planet would take both as a treatment for specific conditions and prophylactically.

    Beyond that (and I know it has not been trialled specifically) but something that can also assist with TBI/Concussion and broad neurological conditions associated with a noisy brain.

    At present, our strategy prevent those applications being explored unless off label, but I would argue that if it works (and it does in pre-clinical models) then
    we are looking at a game changing treatment.

 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.